A
Alan Ashworth
Researcher at University of California, San Francisco
Publications - 589
Citations - 82138
Alan Ashworth is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 134, co-authored 578 publications receiving 72089 citations. Previous affiliations of Alan Ashworth include Imperial College London & Papworth Hospital.
Papers
More filters
Journal ArticleDOI
Lkb1 deficiency causes prostate neoplasia in the mouse.
TL;DR: For the first time, this model establishes a link between the tumor suppressor Lkb1 and prostate neoplasia, highlighting a tumor suppressive role within the mouse and raising the possibility of a similar association in the human.
Journal ArticleDOI
Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components.
Caterina Marchiò,Caterina Marchiò,Marjan Iravani,Rachael Natrajan,Maryou B K Lambros,Felipe C. Geyer,Kay Savage,Suzanne Parry,Narinder Tamber,Kerry Fenwick,Alan Mackay,Fernando Schmitt,Gianni Bussolati,Ian O. Ellis,Alan Ashworth,Anna Sapino,Jorge S. Reis-Filho +16 more
TL;DR: The results suggest that micropapillary differentiation in breast cancer may identify a subgroup of more aggressive ER‐positive breast carcinomas, even in those featuring a mixed histology, and that mixed MPCs are more closely related to pure MPCs than to IDC‐NSTs.
Journal ArticleDOI
The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis
Susan Cleator,Susan Cleator,Trevor J. Powles,Tim Dexter,L G Fulford,Alan Mackay,Ian E. Smith,Haukur Valgeirsson,Alan Ashworth,Mitch Dowsett,Mitch Dowsett +10 more
TL;DR: The non-tumour content of breast cancer samples has a significant effect on gene expression profiles, and consideration of this factor improves accuracy of response prediction by expression array profiling.
Journal ArticleDOI
An In Vivo Functional Screen Identifies ST6GalNAc2 Sialyltransferase as a Breast Cancer Metastasis Suppressor
Nirupa Murugaesu,Marjan Iravani,Antoinette van Weverwijk,Aleksandar Ivetic,Damian A. Johnson,Aristotelis Antonopoulos,Antony Fearns,Mariam Jamal-Hanjani,David Sims,Kerry Fenwick,Costas Mitsopoulos,Qiong Gao,Nick Orr,Nick Orr,Marketa Zvelebil,Stuart M. Haslam,Anne Dell,Helen Yarwood,Christopher J. Lord,Alan Ashworth,Clare M. Isacke +20 more
TL;DR: It is demonstrated that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlighted the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectine-3 inhibitors.
Journal ArticleDOI
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Sophie Postel-Vinay,Ilirjana Bajrami,Luc Friboulet,Richard Elliott,Yari Fontebasso,Nicolas Dorvault,Ken A. Olaussen,Ken A. Olaussen,Fabrice Andre,Fabrice Andre,J-C. Soria,J-C. Soria,Christopher J. Lord,Alan Ashworth +13 more
TL;DR: It is suggested that PARP1/2 inhibitors as a monotherapy could represent a novel therapeutic strategy for NSCLC patients with ERCC1-deficient tumours.